Abstract: Embodiments of the present invention relate to the detection of synchronization marks in data storage and retrieval. According to one embodiment, synchronization marks are detected from the output of a matched filter, upstream of the Viterbi detector. This approach avoids the delay associated with the latency of the Viterbi output, thereby allowing time to align parity framing and to properly start the time-varying trellis. Certain embodiments disclose 34- and 20-bit primary synchronization marks located at the beginning of a data region. Other embodiments disclose 16-, 20-, and 24-bit embedded synchronization marks located within a data region.

Abstract: Embodiments of the present invention relate to the detection of synchronization marks in data storage and retrieval. To detect a synchronization mark, embodiments of the present invention require both pattern matching and proper phase alignment, following a repeating synchronization field. According to one particular embodiment, proper phase alignment following a repeated four bit synchronization field, is utilized in conjunction with pattern matching, to identify a synchronization mark. By allowing a synchronization mark to be identified only with proper phase alignment at the earliest possible occurrence of the synchronization mark, accuracy of synchronization mark detection may be improved.

Abstract: The disclosure provides methods and a composition for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of (5-acetamido-N-(5alpha-cholestan-3alpha-yl)-3,5-dideoxy-2-O-methyl-D-glycero-alpha-D-galacto-non-2-ulopyranosonamide(MCC-257).

Abstract: The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin inhibitor in combination with one or more neurogenic agents. The disclosure also includes compositions and methods for stimulating or activating the formation of new nerve cells based on the application of a renin inhibitor in combination with one or more neurogenic agents.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of one or more biguanides in combination with one or more GSK3-? agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of modafinil, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.

Abstract: The present disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other melatoninergic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The present disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a melanocortin receptor (MCR) modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods of treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of an HMGCR modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat disease.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a disease.

Abstract: The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system. The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.

Abstract: Systems and methods are disclosed for searching or finding music with music, by searching, e.g., for music from a library that has a sound that is similar to a given sound provided as a search query, and to methods and systems for tracking revenue generated by these computer-user interactions, and for promoting music and selling advertising space. These include, inter alia, systems that allow a user to discover unknown music, and systems that allow a user to look for music based directly on queries formed from sounds that the user likes. In some embodiments these queries are comprised of a clip or relatively small segment of a larger media file. A client server system comprising web graphical elements, advertisements and/or other affiliated revenue links, elements in support of the music query and a music player, a database, elements for matching music clips to clips from a library, and elements to present results.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Abstract: Methods and tools for identifying agents and conditions that modulate neurogenesis are disclosed. The disclosure also relates to methods and tools for identifying populations of neural stem cells suitable for transplantation.

Abstract: The invention is directed to the identification and use of additional targets of BIRB 796, imatinib mesylate, and BAY 43-9006. The new targets of BIRB 796, imatinib mesylate, and BAY 43-9006 can be used to screen for suitable therapeutic compounds. Also, novel therapeutic and prophylactic uses for BIRB 796, imatinib mesylate, and BAY 43-9006 are disclosed herein.